Serotonin 1A Agonists and Cognition in Schizophrenia

Completed · Phase 3 · Has a placebo group

Conditions studied: Schizophrenia, Schizoaffective Disorder

In brief

Examines cognitive functioning in patients with schizophrenia or schizoaffective disorder who have been treated with antipsychotic medications. Patients will be assigned to take active medication (Buspar)or placebo along with their prescribed antipsychotic medication for six weeks. Patients' memory and problem-solving ability will be tested before and after medication.

Key facts

Study ID

NCT00178971

Run by

Northwestern University

People needed

60

Starts

2003-01-01

Expected to finish

2004-10-01

Last updated by the study team

2017-06-07

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must meet all of the following criteria to be eligible for participation in the current research study.
• Subjects will be males and females between 18-65 years of age;
• Subjects will have a definite diagnosis by DSM-IV criteria for Schizophrenia or Schizoaffective Disorder;
• The subjects or their legal guardian must sign the informed consent;
• Subjects currently being treated with olanzapine or risperidone for a duration of at least 3 months

You may not qualify if…

• Subjects who are pregnant or lactating
• Subjects who have brain damage and/or neurological disorders
• Subjects who have current substance dependence
• Subjects unable to provide informed consent

Where it is running

• Psychiatric Hospital at Vanderbilt — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.